Parametric Portfolio Associates LLC raised its stake in AxoGen, Inc. (NASDAQ:AXGN) by 0.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,843 shares of the medical equipment provider’s stock after buying an additional 93 shares during the period. Parametric Portfolio Associates LLC’s holdings in AxoGen were worth $113,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the company. State Street Corp raised its stake in shares of AxoGen by 12.8% in the fourth quarter. State Street Corp now owns 352,735 shares of the medical equipment provider’s stock valued at $3,175,000 after buying an additional 39,963 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in shares of AxoGen by 17.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 19,903 shares of the medical equipment provider’s stock valued at $179,000 after buying an additional 2,935 shares during the period. AQR Capital Management LLC acquired a new stake in shares of AxoGen during the fourth quarter valued at $180,000. Teachers Advisors LLC raised its stake in shares of AxoGen by 25.5% in the fourth quarter. Teachers Advisors LLC now owns 48,740 shares of the medical equipment provider’s stock valued at $439,000 after buying an additional 9,893 shares during the period. Finally, Bank of Montreal Can raised its stake in shares of AxoGen by 978.5% in the first quarter. Bank of Montreal Can now owns 14,981 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 13,592 shares during the period. 64.58% of the stock is currently owned by institutional investors and hedge funds.

AxoGen, Inc. (AXGN) opened at 14.70 on Thursday. The firm’s market cap is $488.63 million. AxoGen, Inc. has a 52-week low of $7.65 and a 52-week high of $17.25. The firm’s 50-day moving average price is $15.86 and its 200 day moving average price is $12.85.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The firm had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. AxoGen’s revenue for the quarter was up 46.2% compared to the same quarter last year. On average, equities research analysts forecast that AxoGen, Inc. will post ($0.31) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/axogen-inc-nasdaqaxgn-shares-bought-by-parametric-portfolio-associates-llc.html.

AXGN has been the topic of several research analyst reports. Wedbush reissued an “outperform” rating and set a $14.00 target price (down previously from $17.00) on shares of AxoGen in a research report on Friday, May 19th. ValuEngine raised AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cantor Fitzgerald started coverage on AxoGen in a research report on Thursday, June 29th. They set an “overweight” rating and a $18.00 price target on the stock. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Finally, Leerink Swann started coverage on AxoGen in a research report on Monday, July 31st. They set an “outperform” rating and a $22.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $15.90.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN).

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.